Dimerix (ASX:DXB) opened a pediatric site in Mexico for its ongoing phase three trial investigating the use of DMX-200 in patients with focal segmental glomerulosclerosis, a form of kidney disease, according to a Thursday filing with the Australian bourse.
The trial site is now ready to recruit patients ages 12 to 17 who will be given the same dose as adults, the biopharmaceutical firm said in the filing. An additional 14 pediatric sites will be opened in the US, the UK, and Argentina.
An interim analysis for the trial is set for release in the middle of 2025, per the filing.
Dimerix's shares climbed almost 4% in recent Thursday trade.
Price (AUD): $0.41, Change: $+0.015, Percent Change: +3.85%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.